Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Symptom severity
RCT	247 people	Brief Psychiatric Rating Scale (BPRS) total score 4 weeks with ziprasidone (mean modal dose 149 mg/day) with aripiprazole (mean modal dose 20.9 mg/day) Absolute results not reported	P = 0.098 Cannot reject the null hypothesis of the inferiority of ziprasidone		Not significant
RCT	247 people	Effect size for Positive and Negative Syndrome Scale (PANSS) positive score 4 weeks 1.0 with ziprasidone (mean modal dose 149 mg/day) 1.2 with aripiprazole (mean modal dose 20.9 mg/day)	P = 0.16		Not significant
RCT	247 people	Effect size for PANSS negative score 4 weeks 0.73 with ziprasidone (mean modal dose 149 mg/day) 0.77 with aripiprazole (mean modal dose 20.9 mg/day)	P = 0.71		Not significant
RCT	247 people	Mean change from baseline in PANSS total score over time 2 days –7.0 with ziprasidone (mean modal dose 149 mg/day) –5.5 with aripiprazole (mean modal dose 20.9 mg/day)	P >0.05		Not significant
RCT	247 people	Mean change from baseline in PANSS total score over time 4 days –11.5 with ziprasidone (mean modal dose 149 mg/day) –9.6 with aripiprazole (mean modal dose 20.9 mg/day)	P <0.05	Effect size not calculated	ziprasidone
RCT	247 people	Mean change from baseline in PANSS total score over time 1 week –12.5 with ziprasidone (mean modal dose 149 mg/day) –14.0 with aripiprazole (mean modal dose 20.9 mg/day)	P >0.05		Not significant
RCT	247 people	Mean change from baseline in PANSS total score over time 2 weeks –17.5 with ziprasidone (mean modal dose 149 mg/day) –18.1 with aripiprazole (mean modal dose 20.9 mg/day)	P >0.05		Not significant
RCT	247 people	Mean change from baseline in PANSS total score over time 3 weeks –19.7 with ziprasidone (mean modal dose 149 mg/day) –22.5 with aripiprazole (mean modal dose 20.9 mg/day)	P >0.05		Not significant
RCT	247 people	Mean change from baseline in PANSS total score over time 4 weeks –21.6 with ziprasidone (mean modal dose 149 mg/day) –24.6 with aripiprazole (mean modal dose 20.9 mg/day)	P >0.05		Not significant